Nano cap iBio (NYSEMKT:IBIO) is up 26% premarket on increased volume in reaction to its announcement that
it has inked two Master Services Agreements and a Memorandum of
Understanding (MoU) with the Infectious Disease Research Institute
(IDRI) aimed at advancing its SARS-CoV-2 Virus-Like Particle vaccine
candidate.
Under the agreements, IDRI will support
preclinical development and will oversee clinical trials while the
company will provide process development and manufacturing services.
The MoU calls for a separate agreement within 60
days between the parties if the company opts to include one of IDRI’s
adjuvants in the program (called IBIO-200).
https://seekingalpha.com/news/3559610-ibio-up-26-premarket-on-advancement-of-covidminus-19-vaccine-development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.